GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MEX:INCY) » Definitions » Tax Provision

Incyte (MEX:INCY) Tax Provision : MXN-5,442 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Incyte Tax Provision?

Incyte's tax provision for the three months ended in Dec. 2024 was MXN-2,347 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-5,442 Mil.

Incyte Tax Provision Historical Data

The historical data trend for Incyte's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Tax Provision Chart

Incyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,262.72 7,757.10 -3,674.14 -4,016.38 -5,923.33

Incyte Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,186.11 -1,105.49 -1,004.38 -985.85 -2,346.52

Incyte Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-5,442 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MEX:INCY) » Definitions » Tax Provision
Comparable Companies
MRNA RPRX INSM BMRN UTHR SMMT EXEL TECH SRPT PCVX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
INCY:USA 1INCY:Italy 0J9P:UK ICY:Germany I1NC34:Brazil
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.